Jim MBA - Fate Therapeutics Senior Development
| FATE Stock | USD 3.43 0.22 6.03% |
Executive
Jim MBA is Senior Development of Fate Therapeutics
| Address | 12278 Scripps Summit Drive, San Diego, CA, United States, 92131 |
| Phone | 858 875 1800 |
| Web | https://www.fatetherapeutics.com |
Fate Therapeutics Management Efficiency
The company has return on total asset (ROA) of (0.2084) % which means that it has lost $0.2084 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.4207) %, meaning that it created substantial loss on money invested by shareholders. Fate Therapeutics' management efficiency ratios could be used to measure how well Fate Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. As of May 26, 2024, Return On Tangible Assets is expected to decline to -0.33. In addition to that, Return On Capital Employed is expected to decline to -0.4. At present, Fate Therapeutics' Other Current Assets are projected to increase significantly based on the last few years of reporting. The current year's Net Tangible Assets is expected to grow to about 584.4 M, whereas Non Currrent Assets Other are forecasted to decline to 8,549.Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| JD Esq | Acumen Pharmaceuticals | 53 | |
| Tammy Sarnelli | Amylyx Pharmaceuticals | N/A | |
| Robyn MA | Acumen Pharmaceuticals | N/A | |
| Helen MD | Enliven Therapeutics | 61 | |
| Jeffrey Jasper | Terns Pharmaceuticals | N/A | |
| Sheila MD | Ventyx Biosciences | 54 | |
| Emil MD | Terns Pharmaceuticals | 43 | |
| Minori MD | Compass Therapeutics | 61 | |
| Dr Esq | Enliven Therapeutics | 47 | |
| MD MBA | Compass Therapeutics | 52 | |
| Neil CPA | Compass Therapeutics | 57 | |
| Lindsey Allen | Amylyx Pharmaceuticals | N/A | |
| Linda Arsenault | Amylyx Pharmaceuticals | N/A | |
| Anna Gifford | Compass Therapeutics | N/A | |
| Diana Chung | Terns Pharmaceuticals | N/A | |
| Keith White | Amylyx Pharmaceuticals | N/A | |
Management Performance
| Return On Equity | -0.42 | ||||
| Return On Asset | -0.21 |
Fate Therapeutics Leadership Team
Elected by the shareholders, the Fate Therapeutics' board of directors comprises two types of representatives: Fate Therapeutics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Fate. The board's role is to monitor Fate Therapeutics' management team and ensure that shareholders' interests are well served. Fate Therapeutics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Fate Therapeutics' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Barbara Hickingbottom, Senior Development | ||
| Scott Wolchko, Founder, CEO and President and Director | ||
| Jim MBA, Senior Development | ||
| MS MBA, Chief Officer | ||
| Cindy JD, Corporate Counsel | ||
| Jerome Bressi, Senior Quality | ||
| YuWaye MD, Chief Officer | ||
| Mark DVM, Chief Officer | ||
| Cindy Tahl, General Secretary | ||
| Sarah Cooley, Senior Vice President - Clinical Translation | ||
| Edward III, Chief Officer | ||
| Bahram Valamehr, Chief Development Officer |
Fate Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Fate Therapeutics a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.42 | ||||
| Return On Asset | -0.21 | ||||
| Operating Margin | (26.53) % | ||||
| Current Valuation | 119.22 M | ||||
| Shares Outstanding | 113.83 M | ||||
| Shares Owned By Insiders | 1.58 % | ||||
| Shares Owned By Institutions | 98.42 % | ||||
| Number Of Shares Shorted | 20.81 M | ||||
| Price To Earning | (4.35) X | ||||
| Price To Book | 1.79 X |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.| MSFT | Microsoft | |
| GM | General Motors | |
| CRM | Salesforce |
Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Fate Therapeutics. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in estimate. For information on how to trade Fate Stock refer to our How to Trade Fate Stock guide.You can also try the Commodity Channel module to use Commodity Channel Index to analyze current equity momentum.
Complementary Tools for Fate Stock analysis
When running Fate Therapeutics' price analysis, check to measure Fate Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Fate Therapeutics is operating at the current time. Most of Fate Therapeutics' value examination focuses on studying past and present price action to predict the probability of Fate Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Fate Therapeutics' price. Additionally, you may evaluate how the addition of Fate Therapeutics to your portfolios can decrease your overall portfolio volatility.
| Equity Forecasting Use basic forecasting models to generate price predictions and determine price momentum | |
| AI Portfolio Architect Use AI to generate optimal portfolios and find profitable investment opportunities | |
| Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges | |
| Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets | |
| Global Markets Map Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes |
Is Fate Therapeutics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Fate Therapeutics. If investors know Fate will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Fate Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.92) | Revenue Per Share 0.065 | Quarterly Revenue Growth (0.97) | Return On Assets (0.21) | Return On Equity (0.42) |
The market value of Fate Therapeutics is measured differently than its book value, which is the value of Fate that is recorded on the company's balance sheet. Investors also form their own opinion of Fate Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Fate Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Fate Therapeutics' market value can be influenced by many factors that don't directly affect Fate Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Fate Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Fate Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Fate Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.